Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. In clinical study, cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with PSC.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.